The Long-Term Effect of Dienogest on Bone Mineral Density After Surgical Treatment of Endometrioma

The aim of this study was to evaluate the changing pattern of bone mineral density (BMD) levels after 3 years of dienogest use post endometrioma surgery and investigate the possible predictive factors for BMD reduction. This retrospective study included 44 reproductive-aged women who took dienogest (2 mg/day) and followed up BMD for 3 years after laparoscopic endometrioma surgery from July 2013 to December 2018. In addition, to investigate the predictive factors in the group with decreased BMD, analysis was added for patients with decreased BMD after taking dienogest for 1 year post laparoscopic endometrioma surgery. After 3 years of treatment with dienogest, BMD of both the lumbar spine (− 4.4%) and femur neck (− 3.6%) decreased significantly compared to the baseline levels. Bone loss predominantly occurred during the first year of treatment in the lumbar spine (− 2.4%) and gradually decreased with time during the treatment period. The predictive factors for BMD reduction after dienogest use were evaluated based on a 1-year change in BMD levels of 160 women, but no associated factors were found. This study demonstrated that dienogest use for 3 years was associated with a significant and gradual decrease in BMD and no predictive factors for BMD reduction during the first year of treatment with dienogest were found. These results may be useful in counseling patients regarding long-term effects of dienogest use on reducing BMD levels so that appropriate preventive measures can be taken. Similar content being viewed by others Data Availability Not applicable.

Giudice LC, Kao LC. Endometriosis. Lancet. 2004;364(9447):1789–99. Eisenberg VH, Weil C, Chodick G, Shalev V. Epidemiology of endometriosis: a large population-based database study from a healthcare provider with 2 million members. BJOG. 2018;125(1):55–62. Giudice LC. Clinical practice. Endometriosis. N Engl J Med. 2010;362(25):2389–98. Sinaii N, Plumb K, Cotton L, Lambert A, Kennedy S, Zondervan K, et al. Differences in characteristics among 1,000 women with endometriosis based on extent of disease. Fertil Steril. 2008;89(3):538–45. Kodaman PH. Current strategies for endometriosis management. Obstet Gynecol Clin N Am. 2015;42(1):87–101. Singh SS, Suen MW. Surgery for endometriosis: beyond medical therapies. Fertil Steril. 2017;107(3):549–54. Duffy JM, Arambage K, Correa FJ, et al. Laparoscopic surgery for endometriosis. Cochrane Database Syst Rev. 2014;(4):Cd011031. Kikuchi I, Takeuchi H, Kitade M, Shimanuki H, Kumakiri J, Kinoshita K. Recurrence rate of endometriomas following a laparoscopic cystectomy. Acta Obstet Gynecol Scand. 2006;85(9):1120–4. Guo SW. Recurrence of endometriosis and its control. Hum Reprod Update. 2009;15(4):441–61. Koga K, Takemura Y, Osuga Y, Yoshino O, Hirota Y, Hirata T, et al. Recurrence of ovarian endometrioma after laparoscopic excision. Hum Reprod. 2006;21(8):2171–4. Koga K, Takamura M, Fujii T, Osuga Y. Prevention of the recurrence of symptom and lesions after conservative surgery for endometriosis. Fertil Steril. 2015;104(4):793–801. Falcone T, Flyckt R. Clinical management of endometriosis. Obstet Gynecol. 2018;131(3):557–71. Andres Mde P, Lopes LA, Baracat EC, Podgaec S. Dienogest in the treatment of endometriosis: systematic review. Arch Gynecol Obstet. 2015;292(3):523–9. Zakhari A, Edwards D, Ryu M, Matelski JJ, Bougie O, Murji A. Dienogest and the risk of endometriosis recurrence following surgery: a systematic review and meta-analysis. J Minim Invasive Gynecol. 2020;27:1503–10. Seo JW, Lee DY, Yoon BK, Choi D. Effects of long-term postoperative dienogest use for treatment of endometriosis on bone mineral density. Eur J Obstet Gynecol Reprod Biol. 2017;212:9–12. Harada T, Momoeda M, Taketani Y, Aso T, Fukunaga M, Hagino H, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis--a randomized, double-blind, multicenter, controlled trial. Fertil Steril. 2009;91(3):675–81. Momoeda M, Harada T, Terakawa N, Aso T, Fukunaga M, Hagino H, et al. Long-term use of dienogest for the treatment of endometriosis. J Obstet Gynaecol Res. 2009;35(6):1069–76. Seo JW, Lee DY, Kim SE, Yoon BK, Choi D. Comparison of long-term use of combined oral contraceptive after gonadotropin-releasing hormone agonist plus add-back therapy versus dienogest to prevent recurrence of ovarian endometrioma after surgery. Eur J Obstet Gynecol Reprod Biol. 2019;236:53–7. Harada T, Taniguchi F. Dienogest: a new therapeutic agent for the treatment of endometriosis. Womens Health (Lond). 2010;6(1):27–35. Clarke BL, Khosla S. Physiology of bone loss. Radiol Clin N Am. 2010;48(3):483–95. Klipping C, Duijkers I, Remmers A, Faustmann T, Zurth C, Klein S, et al. Ovulation-inhibiting effects of dienogest in a randomized, dose-controlled pharmacodynamic trial of healthy women. J Clin Pharmacol. 2012;52(11):1704–13. Yu Q, Zhang S, Li H, Wang P, Zvolanek M, Ren X, et al. Dienogest for treatment of endometriosis in women: a 28-week, open-label, extension study. J Women's Health (Larchmt). 2019;28(2):170–7. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24-week, randomized, multicentre, open-label trial. Hum Reprod. 2010;25(3):633–41. Hill P, Wynder EL, Helman P, Hickman R, Rona G, Kuno K. Plasma hormone levels in different ethnic populations of women. Cancer Res. 1976;36(7 PT 1):2297–301. Barbieri RL. Hormone treatment of endometriosis: the estrogen threshold hypothesis. Am J Obstet Gynecol. 1992;166(2):740–5. Gerlinger C, Faustmann T, Hassall JJ, Seitz C. Treatment of endometriosis in different ethnic populations: a meta-analysis of two clinical trials. BMC Womens Health. 2012;12:9. Author information Authors and Affiliations Contributions Conception and design: Hyun-Hye Lim and DooSeok Choi. Data collection: Sung Eun Kim and Hyun-Hye Lim. Analysis and interpretation: Sung Eun Kim and Dong-Yun Lee. Writing the article: Sung Eun Kim, Dong-Yun Lee, and DooSeok Choi. Corresponding author Ethics declarations Conflict of Interest The authors declare that they have no conflict of interest. Ethics Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective study was granted approval by the Institutional Review Board on Samsung Medical Center (IRB approval number: 2019-07-145). Consent to Participate The requirement for required consent was waived due to the retrospective nature of this study. Consent for Publication Not applicable. Code Availability Not applicable. Additional information Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions About this article Cite this article Kim, S.E., Lim, HH., Lee, DY. et al. The Long-Term Effect of Dienogest on Bone Mineral Density After Surgical Treatment of Endometrioma. Reprod. Sci. 28, 1556–1562 (2021). https://doi.org/10.1007/s43032-020-00453-7 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s43032-020-00453-7